Campbell & Co Investment Adviser’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-13,800
| Closed | -$2.16M | – | 1170 |
|
|
2025
Q3 | $2.16M | Buy |
13,800
+8,505
| +161% | +$1.35M | 0.16% | 163 |
|
|
2025
Q2 | $803K | Buy |
+5,295
| New | +$706K | 0.05% | 599 |
|
|
2025
Q1 | – | Sell |
-7,927
| Closed | -$1.46M | – | 1080 |
|
|
2024
Q4 | $1.46M | Buy |
+7,927
| New | +$1.53M | 0.11% | 265 |
|
|
2024
Q3 | – | Sell |
-8,371
| Closed | -$1.73M | – | 1132 |
|
|
2024
Q2 | $1.73M | Buy |
+8,371
| New | +$1.9M | 0.15% | 199 |
|
|
2023
Q3 | – | Sell |
-1,564
| Closed | -$329K | – | 982 |
|
|
2023
Q2 | $329K | Sell |
1,564
-4,392
| -74% | -$874K | 0.06% | 625 |
|
|
2023
Q1 | $1.2M | Buy |
+5,956
| New | +$1.35M | 0.22% | 109 |
|
|
2022
Q3 | – | Sell |
-4,954
| Closed | -$1.06M | – | 740 |
|
|
2022
Q2 | $1.06M | Sell |
4,954
-4,265
| -46% | -$1.04M | 0.29% | 69 |
|
|
2022
Q1 | $2.62M | Buy |
9,219
+4,219
| +84% | +$1.3M | 0.71% | 3 |
|
|
2021
Q4 | $1.88M | Buy |
+5,000
| New | +$1.94M | 0.65% | 8 |
|
|
2021
Q3 | – | Sell |
-1,150
| Closed | -$425K | – | 618 |
|
|
2021
Q2 | $425K | Buy |
+1,150
| New | +$384K | 0.18% | 202 |
|
|
2020
Q1 | – | Sell |
-2,056
| Closed | -$314K | – | 132 |
|
|
2019
Q4 | $314K | Buy |
+2,056
| New | +$285K | 0.1% | 401 |
|
|
2019
Q3 | – | Sell |
-2,838
| Closed | -$403K | – | 629 |
|
|
2019
Q2 | $403K | Buy |
+2,838
| New | +$385K | 0.18% | 203 |
|
|
2018
Q4 | – | Sell |
-2,503
| Closed | -$337K | – | 364 |
|
|
2018
Q3 | $337K | Buy |
2,503
+100
| +4% | +$12.3K | 0.23% | 174 |
|
|
2018
Q2 | $270K | Buy |
+2,403
| New | +$260K | 0.21% | 231 |
|
|
2017
Q3 | – | Sell |
-2,148
| Closed | -$217K | – | 368 |
|
|
2017
Q2 | $217K | Buy |
+2,148
| New | +$198K | 0.2% | 234 |
|
|
2016
Q4 | – | Sell |
-3,652
| Closed | -$304K | – | 152 |
|
|
2016
Q3 | $304K | Buy |
+3,652
| New | +$306K | 0.82% | 48 |
|
|
2015
Q3 | – | Sell |
-6,300
| Closed | -$443K | – | 333 |
|
|
2015
Q2 | $443K | Buy |
+6,300
| New | +$466K | 0.38% | 89 |
|
|
2014
Q3 | – | Sell |
-44,585
| Closed | -$2.39M | – | 201 |
|
|
2014
Q2 | $2.39M | Buy |
+44,585
| New | +$2.45M | 0.95% | 42 |
|
|
2013
Q3 | – | Sell |
-29,275
| Closed | -$1.2M | – | 269 |
|
|
2013
Q2 | $1.2M | Buy |
+29,275
| New | +$1.25M | 0.23% | 128 |
|
Other funds holding CRL
AI
Campbell & Co Investment Adviser's CRL Position: Q4 2025 in Review
Campbell & Co Investment Adviser sold out of Charles River Laboratories (CRL) in Q4 2025, closing a stake of 13,800 shares — an estimated $2.16M sold.
Campbell & Co Investment Adviser first reported a position in CRL in Q2 2013 and held it in 19 quarters. The position peaked at $2.62M in Q1 2022. 580 funds tracked by Wall St. Rank hold CRL as of Q4 2025.
- Campbell & Co Investment Adviser reported no remaining Charles River Laboratories position as of Q4 2025 after selling out during the quarter.
- Campbell & Co Investment Adviser sold 13,800 Charles River Laboratories shares in Q4 2025, an estimated $2.16M.
- Campbell & Co Investment Adviser first reported a position in Charles River Laboratories in Q2 2013 and held it in 19 quarters.
- Campbell & Co Investment Adviser's Charles River Laboratories position peaked at $2.62M in Q1 2022.
- 580 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2025.
Based on Campbell & Co Investment Adviser's 13F filing for Q4 2025, filed 12 Feb 2026.